Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

Antibody Actions

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

AlbuCatcher for Long-Acting Therapeutics.

ACS omega·2024

Same author

Site-Specific Conjugation of Bottlebrush Polymers to Therapeutic Protein via Bioorthogonal Chemistry.

Biomacromolecules·2024

Same author

Enhanced anti-tumor activity of arginine decarboxylase through the incorporation of aromatic amino acids at the multimer-forming interface.

Biotechnology journal·2023

Same author

Computation-Aided Design of Albumin Affibody-Inserted Antibody Fragment for the Prolonged Serum Half-Life.

Pharmaceutics·2022

Same author

Endogenous Aeromonas caviae Endophthalmitis: A Case Report.

Korean journal of ophthalmology : KJO·2022

Same author

Pluronic-Based Nanocarrier Platform Encapsulating Two Enzymes for Cascade Reactions.

ACS applied bio materials·2022

Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential.

Namyeong Kim¹, Inchan Kwon²

¹Department of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), 123 Cheomdan gwagi-ro, Buk-gu, Gwangju, 61005, Republic of Korea.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy

|December 18, 2025

Summary

This summary is machine-generated.

Conditionally activatable antibodies enhance drug safety by activating only at disease sites. This review categorizes strategies like masking domains and payload activation for improved antibody therapeutics.

More Related Videos

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Published on: May 1, 2018

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Related Experiment Videos

Last Updated: Jan 7, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Published on: May 1, 2018

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

Biotechnology
Pharmacology
Immunology

Background:

Antibody-based drugs offer targeted therapy but can cause systemic toxicity.
Activatable antibody platforms aim to restrict drug activity to disease sites, improving the therapeutic index.
Disease-specific microenvironmental cues are leveraged for controlled modulation of antibody function.

Purpose of the Study:

To review and categorize recent advances in conditionally activatable antibody technologies.
To summarize key design principles, examples, and development status of these platforms.
To highlight challenges and emerging trends in activatable antibody design.

Main Methods:

Categorization of activatable antibody strategies into three principal approaches: masking domains, structural rearrangement, and payload activation.
Summary of design principles, representative examples, and preclinical/clinical development status.
Analysis of critical factors including linker chemistry, trigger specificity, and pharmacokinetics.

Main Results:

Activatable antibody technologies are advancing through masking, structural rearrangement, and payload activation strategies.
Key design considerations and translational challenges are identified for each approach.
Emerging trends include multi-input systems and integration with bispecific antibodies and immune cell engagers.

Conclusions:

Conditionally activatable antibodies show significant promise for enhancing therapeutic safety and efficacy.
Rational design guided by understanding linker chemistry, trigger specificity, and pharmacokinetics is crucial.
Future developments integrating advanced modalities will further refine target selectivity and broaden therapeutic applications.